DANC Clinical Risk Calculator
Evaluates isolated Absolute Neutrophil Count against Duffy-null reference intervals (JAMA 2023) and ASH educational guidance.
Clinical Decision Support (CDSS) & International Non-Device Safe Harbor Notice: In accordance with FDA Section 520(o)(1)(E) Non-Device CDSS guidance, EU MDR (2017/745) non-device educational classifications, and WHO Digital Health guidelines, this interactive calculator is an educational decision-support reference reflecting published peer-reviewed algorithms (Merz et al., JAMA 2023; Hibbs et al., JAMA Netw Open 2024). It does not formulate a primary medical diagnosis, establish a physician-patient relationship, or substitute for the independent diagnostic judgment of a licensed hematologist or treating physician.
4-Step Diagnostic Algorithm
Recommended workflow when encountering isolated asymptomatic low neutrophil counts.
Confirm Isolated Mild Neutropenia
Patient presents with persistent resting ANC below conventional reference ranges (e.g., < 1.5 × 10⁹/L; Duffy-null 95% interval: 1.21–5.39 × 10⁹/L per Merz et al., JAMA 2023). Confirm normal hemoglobin, platelets, and peripheral blood smear with absence of dysplasia or immature blasts. Patient is afebrile with no constitutional symptoms. Baseline reversible causes (B12, folate, viral) can be ordered concurrently.
Order ACKR1 Genotyping
Order targeted PCR for the promoter variant rs2814778 (-46T>C) in the ACKR1 gene or blood bank erythrocyte Duffy phenotyping. This is non-invasive, cost-effective, and definitive.
Confirm Benign DANC & Defer Biopsy
Homozygosity for the -46T>C variant confirms benign DANC. In asymptomatic patients with isolated low ANC and normal other lineages, bone marrow aspiration and biopsy are generally unindicated and low-yield per published ASH stewardship recommendations. Reassure the patient and document in EHR.
Immunohematology & Transfusion Nuance
In >99% of Duffy-null patients (-46T>C promoter variant), endothelial ACKR1 expression is intact, conferring natural immune tolerance to the Fy3 antigen, typically preventing the formation of anti-Fy3 antibodies. However, Duffy-null patients lack the Fyª antigen and can form anti-Fyª alloantibodies if exposed to standard blood. Prophylactic rare Fy(a-b-) cross-matching is strictly indicated for chronic transfusion regimens (such as sickle cell disease) to prevent delayed hemolytic reactions.
Differentiating DANC from Pathological Neutropenias
Clinical distinguishing features across common neutropenic etiologies.
| Feature | DANC (Duffy Null) | Autoimmune Neutropenia | Congenital / SCN | MDS / Hypoplasia |
|---|---|---|---|---|
| Typical Baseline ANC | 1.21 – 5.39 × 10⁹/L | Variable (<0.5 to 1.5) | <0.2 × 10⁹/L | <1.0 × 10⁹/L |
| Infection Vulnerability | None (Healthy normal) | Mild to recurrent skin/ENT | Severe pyogenic sepsis | Frequent infections |
| Other Cell Lines | Completely normal Hb & Plt | Usually normal | Monocytosis / Eosinophilia | Anemia, Thrombocytopenia |
| Bone Marrow Reserves | Intact normal myeloid pool | Cellular marrow, absent mature | Myeloid maturation arrest | Dysplasia, ring sideroblasts |
| Confirmatory Test | ACKR1 rs2814778 PCR | Anti-neutrophil antibodies | ELANE, HAX1 sequencing | Bone marrow cytogenetics |
Addressing Chemotherapy & Trial Disparities
Preventing unwarranted oncology treatment interruptions in patients with Duffy-null phenotype.
Standard oncology protocols mandate holding chemotherapy or reducing dosage if pre-cycle ANC falls below 1.5 × 10⁹/L. However, 76.5% of Phase 3 cancer trials enforce eligibility criteria that exclude individuals within the healthy Duffy-null reference range, and 53.5% of systemic regimens impose standard dose modifications in that range (Hibbs et al., JAMA Network Open 2024).
While Duffy-null individuals possess intact myeloid stem cells and normal bone marrow recovery dynamics, optimal genotype-adjusted ANC thresholds for cytotoxic chemotherapy dosing are not yet codified in formal ASCO or NCCN guidelines and remain an active area of clinical research. To advance trial equity under FDA Diversity Action Plan mandates, clinical protocols are increasingly adopting tiered inclusion criteria (e.g., ANC ≥ 1.0 × 10⁹/L for confirmed Duffy-null participants) to prevent unwarranted exclusions without compromising patient safety.
ICD-10 Documentation for DANC
Documenting Duffy-null status cleanly in EHR systems.
"Patient exhibits Duffy-Null Associated Neutrophil Count (DANC) confirmed via ACKR1 rs2814778 genotyping / Fy(a-b-) serology. Baseline ANC 1.21–5.39 × 10^9/L (DANC presentation < 1.5 × 10^9/L) represents physiological normal variant. Asymptomatic with intact myeloid reserve. Routine diagnostic bone marrow examination generally unindicated."
Clinical Summary & Diagnostic Letter Template
Copyable diagnostic explanation letter for evaluating physicians to document DANC for employers, insurers, or medical review boards.
Notice to Physicians & Employers: This template is an educational drafting aid provided exclusively for licensed physicians conducting independent clinical evaluations. DuffyNull.com does not certify patient health status or occupational fitness. Clinical correlation and review of secondary cytopenias are strictly required.
RE: CLINICAL SUMMARY & DOCUMENTATION OF PHYSIOLOGICAL NEUTROPHIL VARIANT (DANC) Patient Name: [Patient Full Name] Date of Birth: [Date of Birth] Evaluation Date: [Date] To Whom It May Concern (Employer / Health Insurer / Occupational Health Service / Medical Review Board): I am writing to provide definitive clinical documentation regarding [Patient Name]'s complete blood count (CBC). Routine laboratory evaluations demonstrate an Absolute Neutrophil Count (ANC) between [e.g., 1.0 – 1.4] × 10⁹/L (or 1000–1400 /μL). This laboratory finding represents Duffy-Null Associated Neutrophil Count (DANC), an established autosomal recessive genetic trait linked to the ACKR1 gene promoter variant (rs2814778, -46T>C). In Duffy-null individuals, mature, functional neutrophils naturally marginate along vascular endothelium and tissue storage pools rather than freely circulating in serum. Per peer-reviewed clinical guidance and the American Society of Hematology (ASH DANC Initiative): 1. Bone marrow cellularity, myeloid maturation, and total-body neutrophil storage pools are completely intact and normal. 2. The patient does NOT have an immune deficiency, bone marrow failure, or leukemia, and routine immune defense against infections is fully preserved. 3. In asymptomatic individuals with isolated low ANC and normal other lineages, no medication, no activity restrictions, and no invasive diagnostic marrow testing are indicated. From a clinical standpoint, the patient exhibits a healthy, benign genetic variant with fully functional immunologic defense. Final occupational fitness or underwriting determinations are subject to comprehensive clinical correlation by the evaluating physician. Sincerely, [Physician Signature & Credentials] [Medical License Number / Clinic Affiliation]
Request Clinician Educational Toolkit
Receive PDF diagnostic flowcharts, clinical case summaries, and patient pamphlets for your hospital or practice.
Frequently Asked Clinical Questions
Evidence-based answers on coding, diagnostic algorithms, medication safety, and pediatric considerations.
What is the appropriate diagnostic coding (ICD-10) and documentation standard for DANC?
In ICD-10-CM, DANC is best documented under D70.8 (Other specified neutropenia) or D70.9 (Neutropenia, unspecified) accompanied by unambiguous provider charting stating: "Benign constitutional variant / Duffy-Null Associated Neutrophil Count (DANC); patient asymptomatic with intact bone marrow reserves."
Supplementary non-pathological diagnostic codes include Z14.8 (Genetic carrier / constitutional trait) or R79.89 (Other specified abnormal findings of blood chemistry). Explicit documentation is critical to suppress automated electronic health record (EHR) interruptive alerts, avert inappropriate antibiotic prophylaxis, and prevent unnecessary specialist referrals.
How should chemotherapy, immunosuppressive agents, or clozapine be managed in patients with DANC?
Individuals with DANC possess intact myeloid stem cells and normal endogenous granulopoiesis. In oncology practice, prospective trials demonstrate equivalent neutrophil nadir-to-recovery kinetics compared to non-Duffy-null peers. Unwarranted dose reductions or cycle postponements based strictly on standardized threshold cutoffs (>1.5 × 10⁹/L) compromise curative relative dose intensity (RDI) without safety benefit.
For clozapine administration, the FDA Clozapine REMS program explicitly accommodates patients with documented DANC (historically Benign Ethnic Neutropenia), establishing an adjusted qualification baseline of ANC ≥ 1.0 × 10⁹/L (rather than ≥1.5 × 10⁹/L) with adapted cessation triggers.
What is the recommended diagnostic algorithm to evaluate an asymptomatic patient with isolated low ANC?
For an asymptomatic individual presenting with isolated resting ANC below conventional thresholds (e.g., < 1.5 × 10⁹/L; Duffy-null 95% reference interval: 1.21–5.39 × 10⁹/L per Merz et al., JAMA 2023) and normal red blood cell and platelet parameters:
- Step 1: Confirm Isolated Neutropenia & Stability: Review prior complete blood counts (CBCs) over 3–6 months to confirm chronicity. Reversible nutritional etiologies (serum B12, folate, copper) and viral serologies can be ordered concurrently at baseline.
- Step 2: Order ACKR1 Molecular Genotyping: Order targeted PCR for the promoter variant rs2814778 (-46T>C / c.-67T>C) or blood bank erythrocyte Duffy phenotyping [Fy(a-b-)].
- Step 3: Confirm Benign DANC & Defer Marrow Biopsy: Homozygosity confirms DANC. In the absence of red flags (B-symptoms, lymphadenopathy, organomegaly, peripheral blasts, or multilineage cytopenias), invasive bone marrow aspiration/biopsy is clinically unnecessary per ASH stewardship guidance.
- Step 4: Transfusion Guidance & EHR Documentation: Document genetic trait (ICD-10 D70.8 / Z14.8) in patient charting to suppress EHR alert fatigue and educate the patient on routine transfusion safety (endothelial ACKR1 intact in >99%).
Why are historical demargination challenge tests (hydrocortisone, epinephrine, G-CSF) contraindicated?
Pharmacological challenge testing was conceived decades ago to demonstrate mobilization of marginal pool granulocytes into circulation. However, recombinant G-CSF challenge exposes patients to severe musculoskeletal pain, splenic enlargement, and rare splenic rupture. Epinephrine and hydrocortisone challenge tests suffer from erratic pharmacodynamics and lack diagnostic specificity.
Molecular ACKR1 PCR genotyping or immunohematology blood bank serotyping is completely non-invasive, 100% specific, and renders in vivo pharmacological challenge testing obsolete and clinically contraindicated.
At what age does DANC manifest in pediatric patients?
Prospective longitudinal cohorts in pediatric hematology (including clinical investigation NCT06908616 at Emory University) show that the divergence in absolute neutrophil counts between Duffy-null and Duffy-positive children emerges between 6 and 12 months of life. This timing mirrors the developmental switch from fetal hemoglobin and neonatal hematopoiesis to adult erythroid regulatory networks.
Cord blood ACKR1 DNA PCR testing provides definitive molecular diagnosis at birth, establishing normal individualized baselines before pediatric CBC panels are drawn.